Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
about
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolismReducing the risk of venous thromboembolism using apixaban - patient perspectives and considerations. Should more attention be given to females?Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the ArtManaging pulmonary embolism using prognostic models: future concepts for primary careDiagnosis and Treatment of Lower Extremity Deep Vein Thrombosis: Korean Practice GuidelinesPhase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results.Duration of anticoagulant therapy for venous thromboembolism: balancing benefits and harms on the long term.Thrombo-prophylaxis in acutely ill medical and critically ill patients.Different Finite Durations of Anticoagulation and Outcomes following Idiopathic Venous Thromboembolism: A Meta-Analysis.Discovery of Intra-Abdominal Hemorrhage during Hernioplasty in a Patient Taking RivaroxabanTarget-specific oral anticoagulants: should we switch from warfarin?The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry.Evidence for treatment of muscular vein thrombosis in orthopaedic patients.Use of ASA after warfarin for unprovoked VTE.How to prevent, treat, and overcome current clinical challenges of VTE.New anticoagulants for the treatment of venous thromboembolism.
P2860
Q24194466-0EEF03A3-DB79-4728-99A0-18EF7206326EQ26766547-AC1B54C1-2CEA-4EC9-8C20-4FC369E44859Q26776112-0ABED8C8-8A31-4477-A8AE-9FF17975ADC6Q26830769-6610A32E-AA10-44F7-9EF3-06DC5B712C54Q28072833-40516690-093F-4BD6-A3E9-21381D73EE7DQ33663404-99B78644-3B07-432D-9E53-04B8EA88C5F3Q34284224-8A6E21E4-94E2-4B64-841A-91D8EEECEAF7Q35199938-B34CB6DA-A606-458C-A7C7-7E6D4DAB64DEQ35536251-6038BC49-6046-4170-A0DB-EED3AE3F1753Q35540804-87B2FA90-BA94-4737-B020-D17C3C1EA8F0Q35758778-EB808BEF-235C-4BBE-B46A-DC848F48113BQ36202176-0684D0D8-D90C-4B19-9716-9608EF7A8756Q37115422-D8298913-177F-4248-99D6-F64DAB02390AQ37230528-0090183F-07B5-494F-846E-B10AB29F2DECQ37903951-2D0092E0-6A79-44D2-BEC2-E66681C33A83Q38831847-AC18FA35-10D3-45A6-870A-92329522F2DD
P2860
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
@ast
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
@en
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
@en-gb
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
@nl
type
label
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
@ast
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
@en
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
@en-gb
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
@nl
prefLabel
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
@ast
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
@en
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
@en-gb
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
@nl
P2860
P3181
P1476
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
@en
P2093
Barbara A Hutten
Martin H Prins
P2860
P3181
P356
10.1002/14651858.CD001367.PUB2
P577
2006-01-25T00:00:00Z